Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Mark Alles’ Biotech Gets $96M for ADCs From UCLA Lab

Summary by endpoints.news
An antibody-drug conjugate biotech led by the former Celgene CEO has collected $96 million to run a registrational trial in the CLDN6 field. TORL BioTherapeutics' Series C is a far cry ...
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

endpoints.newsendpoints.news

Mark Alles’ biotech gets $96M for ADCs from UCLA lab

An antibody-drug conjugate biotech led by the former Celgene CEO has collected $96 million to run a registrational trial in the CLDN6 field. TORL BioTherapeutics' Series C is a far cry ...

Read Full Article
thebesttimes.comthebesttimes.com
Reposted by
The AI JournalThe AI Journal

TORL BioTherapeutics Secures $96M Series C Financing and Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2025 European Society of Medical Oncology Congress

Secured $96M Series C Financing; Total Raised Since 2019 Founding Exceeds $450M

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

thebesttimes.com broke the news in on Tuesday, October 7, 2025.
Sources are mostly out of (0)

Similar News Topics

UCLA icon

UCLA

Maryland icon

Maryland

News
For You
SearchBlindspotLocal